No Brainer Approaches to Neutrophilic Dermatoses
At the 2025 ODAC Dermatology conference, Dr. Anthony Fernandez, MD, PhD gave an informative presentation titled, No-Brainer Approaches to Neutrophilic Dermatoses. His presentation focused on discussing the clinical presentation, differential diagnosis considerations, and treatment options of pyoderma gangrenosum and Sweet syndrome.
Pyoderma Gangrenosum (PG)
Pyoderma gangrenosum typically present …
At the 2025 ODAC Dermatology conference, Dr. Anthony Fernandez, MD, PhD gave an informative presentation titled, No-Brainer Approaches to Neutrophilic Dermatoses. His presentation focused on discussing the clinical presentation, differential diagnosis considerations, and treatment options of pyoderma gangrenosum and Sweet syndrome.
Pyoderma Gangrenosum (PG)
Pyoderma gangrenosum typically present … Continue reading "No Brainer Approaches to Neutrophilic Dermatoses"
As dermatologists, we recognize that chronic itch is a complex and often debilitating condition that significantly impacts our patients' quality of life, affecting their physical health, mental well-being, and daily activities. Chronic itch can be especially challenging to diagnose and treat, particularly in patients with skin of color, who may experience unique clinical manifestations and complic … 
It’s an exciting time for new therapies in atopic dermatitis with several therapies recently approved or in late-stage development. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Baltimore dermatologist Dr. Shawn Kwatra, who outlined the new treatment options. From therapies that target IL-13 and IL-31 to JAK inhibitors, dermatology cl … 
Collagen vascular diseases encompass a group of autoimmune disorders that can have a profound impact on an individual's health and quality of life. At the 2023 Skin of Color Update, Dr. Ted Rosen, Professor and Vice-Chair of Dermatology at Baylor College of Medicine, explained how these conditions uniquely impact individuals with skin of color.
Missed the lecture?? Explore key insights and pear … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 